Robin L. Jones, MBBS, MRCP, MD, Institute of Cancer Research in London, UK, discusses the persistent interest in utilizing MDM2 inhibitors for well and dedifferentiated liposarcoma. Ongoing trials explore various agents targeting MDM2 in this disease, indicating the evolving landscape of treatment options. Prof. Jones emphasizes the exploration of combination schedules in dedifferentiated liposarcoma and the crucial quest for improved predictive markers of treatment response. Identifying the subset of patients most likely to benefit from MDM2 inhibitor treatment is a key focus. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
